Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$43.66

0.03 (0.07%)

, BIIB

Biogen

$341.41

-2.67 (-0.78%)

07:57
08/07/18
08/07
07:57
08/07/18
07:57

Ionis Pharmaceuticals transferred with a Hold at Stifel

Stifel transferred coverage of Ionis Pharmaceuticals (IONS) to analyst Paul Matteis, who set a Hold rating and $48 price target on the shares. The Biogen (BIIB) deal, while validating, limits some of the future upside for Ionis, Matteis tells investors. Also, despite his long-term bullishness on the TTR amyloidisis opportunity, he is below consensus for the first year of the launches for Tegsedi and Waylivra.

IONS

Ionis Pharmaceuticals

$43.66

0.03 (0.07%)

BIIB

Biogen

$341.41

-2.67 (-0.78%)

  • 30

    Aug

  • 06

    Oct

IONS Ionis Pharmaceuticals
$43.66

0.03 (0.07%)

06/20/18
LEHM
06/20/18
DOWNGRADE
Target $45
LEHM
Underweight
Ionis Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Ionis Pharmaceuticals (IONS) to Underweight and lowered her price target for the shares to $45 from $52 after PTC Therapeutics (PTCT) reported competing spinal muscular atrophy data. Wang this morning also upgraded PTC to Equal Weight from Underweight.
06/20/18
LEHM
06/20/18
NO CHANGE
LEHM
Barclays upgrades PTC to Equal Weight, downgrades Ionis to Underweight
Barclays analyst Gena Wang upgraded PTC Therapeutics (PTCT) to Equal Weight from Underweight while downgrading Ionis Pharmaceuticals (IONS) to Underweight from Equal Weight. The analyst raised her price target on the former to $40 from $26 and lowered her price target on the latter to $45 from $52. Following PTC's new data in spinal muscular atrophy data, the analyst believes its risdiplam has "disruptive potential" to Ionis and Biogen's (BIIB) Spinraza.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis approval narrower than expected, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says the European approval of Tegsedi announced this morning Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) for the treatment of stage 1 or stage 2 polyneuropoathy in adult patients with hATTR was narrower than he originally expected. The indication is narrower than the broader hATTR patient population, inclusive of both cardiomyopathy and polyneuropathy, but makes sense considering that the pivotal trial primarily enrolled patients with stage 1 and 2 polyneuropathy, Van Buren tells investors in a research note. The analyst adds that while the approval is a positive development and Tegsedi represents the largest near-term pipeline opportunity for Ionis, he wants to observe positive early launch metrics and confirmation of the opportunity before getting more constructive on the shares. He keeps a Neutral rating on Ionis with a $50 price target.
07/23/18
OPCO
07/23/18
NO CHANGE
Target $400
OPCO
Outperform
Oppenheimer anticipating potential volatility ahead for Biogen
Oppenheimer analyst Jay Olson anticipates Biogen (BIIB) volatility driven by Q2 results along with AD presentations at AAIC that include promising BAN2401 data, which was recently top-lined. The analyst expects a focus on ADCOMS component scores and effect sizes for BAN2401. With regards to Q2 results, Olson expects top-line growth of 4% and non-GAAP EPS of $3.95 which is impacted by the Ionis Pharmaceuticals (IONS) deal upfront payment. Additionally, he expects continued strong Spinraza and biosimilar growth. Olson reiterates an Outperform rating and $400 price target on Biogen's shares.
BIIB Biogen
$341.41

-2.67 (-0.78%)

07/26/18
07/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. PIPER CUTS 3D SYSTEMS TO UNDERWEIGHT: Piper Jaffray analyst Troy Jensen downgraded 3D Systems (DDD) to Underweight from Neutral with a $10 price target. He believes competition for the company's main product lines is intensifying. The analyst also thinks 3D will need to increase spending on direct sales, customer support and consulting, meaning "meaningful profitability" will likely be more challenged than revenue growth throughout 2018. He views the stock as overvalued. While Jensen continues to believe the overall 3D printing industry is "growing rapidly," he remains cautious on shares of 3D Systems and Stratasys (SSYS). He reiterated a Neutral rating on the latter. OPCO CUTS E.L.F. TO PERFORM: Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty. FACEBOOK GETS MULTIPLE DOWNGRADES AFTER Q2 EARNINGS: Nomura Instinet analyst Mark Kelley downgraded Facebook (FB) to Neutral from Buy after the company delivered "underwhelming" Q2 results and guided for revenue growth deceleration through the end of the year. The revenue guidance paired with the expectation for mid-30% operating margins in the medium term or possibly longer means consensus numbers will be cut "drastically," he said. He lowered his price target on Facebook shares to $183 from $228. Facebook was also downgraded to Neutral from Buy by UBS analyst Eric Sheridan, who also lowered his price target for the shares to $180 from $212, and to Outperform from Strong Buy at Raymond James. Facebook shares are down over 19% in late morning trading. PIPER SAYS BIOGEN SELLOFF A BUYING OPPORTUNITY: Biogen (BIIB) shares "will recover and continue to work" into aducanumab's full Phase 3 data in 2020, Piper Jaffray analyst Christopher Raymond told investors. With the stock having run up into these data, the analyst said he understood the "sell-the-news" phenomenon. He believes, however, that the fundamental concerns he's heard from investors "don't seem to hold water." The analyst said to buy Biogen shares on the selloff. He kept an Overweight rating on the name with a $400 price target.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $400
PIPR
Overweight
Piper recommends Biogen shares after meeting with management
After hosting investor meetings with Biogen investor relations this week, Piper Jaffray analyst Christopher Raymond continues to recommend purchase of the shares. The analyst came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond tells investors in a research note. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on shares of Biogen. He keeps an Overweight rating on the name with a $400 price target.
08/01/18
08/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JEFFERIES UPGRADES DROPBOX TO BUY: Jefferies analyst John DiFucci upgraded Dropbox (DBX) to Buy from Hold with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation," he stated. Dropbox is up 4.7% in late morning trading. JEFFERIES UPGRADES PAPA JOHN'S: Jefferies analyst Alexander Slagle upgraded Papa John's (PZZA) to Buy from Hold and raised his price target for the shares to $58 from $52. The stock, down 50% from highs, now reflects the likelihood that fundamentals will get worse before improving, Slagle said. After reviewing the company's potential path to recovery and possible strategic actions that could create shareholder value, the analyst has a bull case of $75 per share. He thinks this outweighs the bear case, or downside risk, of $35 per share. SAREPTA UPGRADED AFTER PULLBACK: Morgan Stanley analyst Matthew Harrison upgraded Sarepta Therapeutics (SRPT) to Overweight from Equal Weight, noting that the stock has given up much of the gains it saw when its initial DMD gene therapy data was announced. He sees the pullback as an opportunity to own the stock near pre-DMD gene therapy levels without taking the binary risk. He doesn't think a major bear case has emerged on the prospects for the company's DMD gene therapy program and he sees major catalysts in the second half of this year that he believes the market is missing. Harrison has a $163 price target on Sarepta shares. PIPER CUTS SHOPIFY TO NEUTRAL: Piper Jaffray analyst Michael Olson downgraded Shopify (SHOP) to Neutral from Overweight and lowered his price target to $145 from $155, saying that Shopify's Q2 was "good, but not good enough" with monthly recurring revenue below investor expectations. While Olson said Shopify is performing well, he believes their performance is mostly reflected in the stock's current valuation. PIPER RECOMMENDS BIOGEN AFTER MANAGEMENT MEETING: After hosting investor meetings with Biogen (BIIB) investor relations this week, Piper Jaffray analyst Christopher Raymond came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond said. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on Biogen. He kept an Overweight rating on shares with a $400 price target.
08/07/18
STFL
08/07/18
INITIATION
Target $394
STFL
Biogen resumed with a Buy at Stifel
Stifel analyst Paul Matteis resumed coverage of Biogen with a Buy rating and a $394 price target, citing his above consensus projections for Spinraza in Spinal Muscular Atrophy and his view that the odds of success for Aducanumab in Alzheimer's are "modestly better than 50/50." While there are real reasons to believe "this time is different" with Aducanumab, Matteis does worry that the floor value in a negative scenario for the Alzheimer's drug might be lower than some think, he tells investors.

TODAY'S FREE FLY STORIES

SYMC

Symantec

$19.36

-0.22 (-1.12%)

05:00
06/17/19
06/17
05:00
06/17/19
05:00
Upgrade
Symantec rating change  »

Symantec upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OGE

OGE Energy

$43.42

0.17 (0.39%)

04:56
06/17/19
06/17
04:56
06/17/19
04:56
Initiation
OGE Energy initiated  »

OGE Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
06/17/19
06/17
04:55
06/17/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
CLSA India economics & strategy luncheon meeting »

India Strategist…

IR

Ingersoll-Rand

$124.65

0.31 (0.25%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Ingersoll-Rand management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

NTGN

Neon Therapeutics

$4.76

-0.15 (-3.06%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Neon Therapeutics management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 18

    Jun

NVTA

Invitae

$19.20

-0.43 (-2.19%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Invitae participates in a conference call with JPMorgan »

Life Science Tools &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 06

    Aug

DL

China Distance Education

$5.41

(0.00%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
China Distance Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

QRTEA

Qurate Retail

$12.83

-0.4 (-3.02%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Qurate Retail management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 20

    Jun

04:55
06/17/19
06/17
04:55
06/17/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

GNL

Global Net Lease

$19.58

0.13 (0.67%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Global Net Lease management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ITT

ITT

$62.33

-0.54 (-0.86%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
ITT management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

TGODF

The Green Organic Dutchman

$0.00

(0.00%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
The Green Organic Dutchman Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Stephens banking analysts to hold an analyst/industry conference call »

Analysts, along with the…

AGTC

Applied Genetic

$3.89

0.04 (1.04%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Applied Genetic management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

AMRS

Amyris

$3.93

-0.16 (-3.91%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Amyris management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

IONS

Ionis Pharmaceuticals

$62.07

-1.79 (-2.80%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Ionis Pharmaceuticals management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

RTIX

RTI Surgical

$4.20

-0.09 (-2.10%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
RTI Surgical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

DEI

Douglas Emmett

$41.26

-0.24 (-0.58%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Douglas Emmett management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

LH

LabCorp

$166.42

-1.525 (-0.91%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
LabCorp management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

04:55
06/17/19
06/17
04:55
06/17/19
04:55
General news
Empire State Mfg Survey General Business Conditions Index to be reported at 08:30 »

June Empire State Mfg…

CL

Colgate-Palmolive

$73.34

0.57 (0.78%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Colgate-Palmolive management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 26

    Jul

RGSE

RGS Energy

$0.00

(0.00%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
RGS Energy to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 25

    Jun

ADAP

Adaptimmune

$3.60

-0.09 (-2.44%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Adaptimmune management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 19

    Jun

ASUR

Asure Software

$6.76

0.04 (0.60%)

04:55
06/17/19
06/17
04:55
06/17/19
04:55
Conference/Events
Asure Software management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.